🔉📷 Join us at the upcoming bi-weekly @myCARG
meeting!
1/7 at 11am PT/2pm ET Co-leads: Drs. @WilliamDale_MD and Mostafa Mohamed
*Agenda*
-Announcements
-ACS Resources & Data Availability: Dr. Peoples
-Management of Polypharmacy in Older Adults w/ Advanced Cancer: Dr. Mohamed
@rochgerionc @m_refaat84@WilmotCancer I've loved the medication related outcome subanalysis work that has emerged from GAP70+! Has formed much of the backbone of my PhD thesis!
Honored to present at SoFOG -DIALOG Meeting, a collaborative French group dedicated to advancing geriatric oncology research. During the virtual session, I shared results from our article in JAMA, which assessed chemotherapy dosing decisions in older adults with advanced cancer.
WCI's @DrAllisonMags and @MelissaLoh21 share insights on recent guidelines on geriatric assessment for clinicians, out now in @CACancerJournal.
Study: https://t.co/JBWWmlqJ2K
Story: https://t.co/29QPlEUUPv
#URochesterResearch#gerionc
Honored to present our work using GAP70+ data at #ASCO24: Geriatric assessment guided tx modification improved tolerability in older adults with advanced cancer compared to oncologist’s estimate only. More work is needed to optimize chemo dosing in this population @WilmotCancer
@m_refaat84 from @WilmotCancer presents results showing that chemo modifications based on geriatric assessment have protective effect compared to the oncologists “eyeball” test (usual care)
Less grade 3+ toxicity and 2ndary dose reduction
#ASCO24#gerionc
Thrilled to attend the ASCO for the first time as an oral presenter! I will share our results on 1ry tx modification in older adults with cancer at the GeriOnc Clinical Science Symposium on Saturday at 1:15 pm. Looking forward to the discussions! @WilmotCancer@UR_Med#ASCO24